Drug Type CAR-T |
Synonyms BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics), BCMA-CS1 cCAR |
Target |
Mechanism BCMA modulators(B-cell maturation protein modulators), SLAMF7 modulators(SLAM family member 7 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plasma cell myeloma refractory | Phase 1 | CN | 31 Aug 2018 | |
Plasma cell myeloma refractory | Phase 1 | CN | 31 Aug 2018 | |
Relapse multiple myeloma | Phase 1 | CN | 31 Aug 2018 | |
Relapse multiple myeloma | Phase 1 | CN | 31 Aug 2018 |